We were early adopters of 3D conformal radiotherapy, intensity modulated radiotherapy, and tomotherapy on the Canadian scene. We are interested in studies of improved patient outcome using advanced image guided RT technologies. These studies use physician -and patient - derived toxicity reporting, including in depth quality of life assessment in head and neck cancer and prostate cancer. We are also exploring ways in which advanced functional imaging modalities can enhance targeting in head and neck and GU malignancies.

We have been interested for the last several years in the genetic basis for inter-individual variation in radiation treatment toxicity outcomes. Using single nucleotide polymorphism (SNP) sequencing, key candidate genes in DNA damage repair, tissue remodeling and homeostasis are analyzed for their potential association with documented toxicity. We also use comprehensive dosimetry databases to provide the physical dose correlate of archival treatments. We collaborate in this work with the Radiation Therapy Oncology Group Translational Research Program, and since 2009, with the international Radiogenomics Consortium.